DRTS ALPHA TAU MEDICAL LTD.

Alpha Tau to Participate in Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference

Alpha Tau to Participate in Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference

JERUSALEM, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Company plans to participate in Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 1, 2023 taking place at Citi HQ Conference Center in New York City.

Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference:

Date: Wednesday, March 1, 2023

Location: Citi HQ Conference Center

If you would like to schedule a 1:1 meeting, please contact your Citi representative.

About Alpha DaRT™

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

Investor Relations Contact



EN
21/02/2023

Underlying

DRTSALPHA TAU MEDICAL LTD.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALPHA TAU MEDICAL LTD.

 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau Announces First Quarter 2025 Financial Results and Provides ...

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update - Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -       - 75% systemic objective response rate (ORR) and 37.5% complete response rate meaningfully higher thus far than historical Keytruda® monotherapy data in Jan-2025 interim read out of a combination trial of Alpha DaRT and Keytruda in ...

May 19, 2025 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Direct...

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: , ) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., (“Oramed”), has been appointed to the Company’s Board of Directors (“Board”). The appointment follows the recent closing of a strategic investment between the Company and an affiliate of Oramed. “Nadav is a fantasti...

May 12, 2025 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau to Participate in May Investor Conferences

Alpha Tau to Participate in May Investor Conferences JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will presentation in the following investor conferences in May 2025. Event:H.C. Wainwright 3rd Annual BioConnect Investor ConferenceFormat:Fireside ChatDate:May 20, 2025Time:3:30 – 4:00PM ETLocation:New York, NY Event:Lytham Partners Spring 2025 Investor ConferenceFormat:1x1 MeetingsDate:May 29, 2025Locati...

May 6, 2025 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offerin...

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S. trial approvals, expansion into multiple internal organ applications, scaling up of manufacturing capabilities, and commercial preparations underway JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cance...

April 28, 2025 1 EN
 PRESS RELEASE
Free
DRTS ALPHA TAU MEDIC...

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with ...

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with recurrent glioblastoma (GBM) using the Alpha DaRT technology. “This is very exciting news for patients suffering from glioblastoma, a highly aggressive form of brain cancer wit...

April 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch